Case analysis · Calls & text messages

Physicians Healthsource v. Boehringer Ingelheim: A Free Dinner Fax Can Be an Ad

Drug companies love sponsoring free dinners for doctors. Fax an invitation to one without permission, and you may have sent an "unsolicited advertisement." In Physicians Healthsource, Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 15-288-cv, 847 F.3d 92 (2d Cir. Feb. 3, 2017), the Second Circuit revived a junk fax class action over exactly that kind of invitation.

By Adam YoungPublished 2 min read
On this page

The fax

On April 6, 2010, Boehringer faxed Physicians Healthsource an invitation for one of its doctors to a free "dinner meeting" titled "It's Time to Talk: Recognizing Female Sexual Dysfunction and Diagnosing Hypoactive Sexual Desire Disorder." The fax said the program was sponsored by Boehringer and would cover the conditions' "pathophysiology models, epidemiology, and diagnosis." It had no opt-out notice.

At the time, Boehringer had asked the Food and Drug Administration (FDA) to approve a drug called flibanserin to treat this condition. Until approval, FDA rules barred Boehringer from promoting it.

Physicians Healthsource filed a class action in 2014 under the Telephone Consumer Protection Act (TCPA), as amended by the Junk Fax Prevention Act. The District of Connecticut dismissed, finding nothing showing the dinner was a pretext for pitching a product.

What the court held

Judge Winter wrote for the panel, joined by Judges Jacobs and Leval. The court vacated and remanded.

The key question was whether the fax was an "unsolicited advertisement," meaning material advertising "the commercial availability or quality of any property, goods, or services." A 2006 Federal Communications Commission (FCC) rule says faxes promoting free goods or services, like free seminars, are unsolicited advertisements, noting that free seminars often "serve as a pretext" for advertising.

The Third Circuit’s free opioid seminar fax decision

The court agreed a fax needs a commercial purpose. But at the pleading stage, if the business faxes an invitation to a free seminar on a subject that relates to the business, then it's plausible that the fax had that commercial purpose: "Businesses are always eager to promote their wares and usually do not fund presentations for no business purpose." The defendant can rebut that later, after discovery, with things like the agenda, slides or attendee testimony.

The court gave a memorable example. If the Handy Widget Company invited people to a lecture on Greek philosophers, no claim. But if it invites them to a seminar on making widgets more productive, the claim is stated.

Here, Boehringer is in the business of treating medical conditions, it sponsored the dinner and it sent the invite to a doctor it would want prescribing its drugs. The pending application for flibanserin was also relevant. There is nothing limiting the statute to products already on the market.

The concurrence

Judge Leval agreed but wrote separately, addressed to other courts. He suggested the 2006 rule could be read more broadly: faxes from commercial entities offering free goods or services may simply be treated as ads, pretext or not. He noted nonprofits are likely outside that rule.

Why this matters

For pharma, medical device and other companies, a "free educational event" fax isn't automatically safe.

Practical points:

  1. Consider event invitations that are related to your business as potential ads.
  2. Get prior express permission before faxing them.
  3. Retain agendas and materials, so that they may serve as your rebuttal evidence.

Read the Second Circuit's opinion and concurrence in Physicians Healthsource v. Boehringer Ingelheim.

Not legal advice. TCPA.com provides general information, not legal advice, and is not a substitute for the advice of an attorney. Do not rely on it. Verify any action with your own licensed lawyer before you take it. See our Terms of Use.

Primary sources

  1. Opinion and concurrence, Physicians Healthsource, Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 15-288-cv (2d Cir. Feb. 3, 2017) (opinion) (concurrence)
  2. Opinion and concurrence, Physicians Healthsource, Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 15-288-cv (2d Cir. Feb. 3, 2017) (opinion) (concurrence) (2)
  3. Opinion and concurrence, Physicians Healthsource, Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 15-288-cv (2d Cir. Feb. 3, 2017) (opinion) (concurrence) (3)
  4. Opinion of the court followed by Judge Leval's concurrence, Physicians Healthsource, Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 15-288-cv (2d Cir. Feb. 3, 2017).
Adam Young, CEO of Ringba, Miami, Florida

About the Author: Adam Young

Adam Young is a 42-year-old entrepreneur from Miami, Florida. He is the CEO of Ringba, a call tracking and pay per call platform. Adam Young has been in telecom, call routing and performance marketing for over a decade, and is the author of The Pay Per Call Revolution. At TCPA.com, Adam Young writes about the Telephone Consumer Protection Act (TCPA), robocall enforcement, tech support fraud cases and what actions by the Department of Justice (DOJ), Federal Trade Commission (FTC) and Federal Communications Commission (FCC) mean for companies that make calls. His goal is to help companies stay compliant and keep scammers off the phone network.

More from Adam Young

Topics